Cargando…

Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS‐HF

BACKGROUND: Ultrafiltration is not commonly used because of higher incidence of worsening renal function without improved decongestion. We examined differential outcomes of high versus low fluid removal and preserved versus reduced ejection fraction (EF) in CARRESS‐HF (Cardiorenal Rescue Study in Ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fudim, Marat, Brooksbank, Jeremy, Giczewska, Anna, Greene, Stephen J., Grodin, Justin L., Martens, Pieter, Ter Maaten, Jozine M., Sharma, Abhinav, Verbrugge, Frederik H., Chakraborty, Hrishikesh, Bart, Bradley A., Butler, Javed, Hernandez, Adrian F., Felker, G. Michael, Mentz, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955382/ https://www.ncbi.nlm.nih.gov/pubmed/33289458 http://dx.doi.org/10.1161/JAHA.119.015752

Ejemplares similares

Hyperkalemia in Heart Failure: Probably Not O“K”
por: Fudim, Marat, et al.
Publicado: (2018)

Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis
por: Fudim, Marat, et al.
Publicado: (2020)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

High‐Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network
por: Fudim, Marat, et al.
Publicado: (2018)

Tackling Inflammation in Heart Failure With Preserved Ejection Fraction: Resurrection of Vagus Nerve Stimulation?
por: Kittipibul, Veraprapas, et al.
Publicado: (2022)

Additive value of dobutamine stress echocardiography in patients with an anomalous origin of a coronary artery
por: Lameijer, Heleen, et al.
Publicado: (2015)

A patient with recurrent syncope—it does matter how slow and long you go
por: Roseboom, Eva, et al.
Publicado: (2023)

A patient with recurrent syncope—it does matter how slow and long you go
por: Roseboom, Eva, et al.
Publicado: (2023)

Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study
por: Januzzi, James L., et al.
Publicado: (2022)

Role of Volume Redistribution in the Congestion of Heart Failure
por: Fudim, Marat, et al.
Publicado: (2017)

Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply
por: Damman, Kevin, et al.
Publicado: (2020)

Pain score, desire for pain treatment and effect on pain satisfaction in the emergency department: a prospective, observational study
por: van Zanden, Judith E., et al.
Publicado: (2018)

Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta‐blockers
por: Varian, Kenneth D., et al.
Publicado: (2020)

Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort
por: Fudim, Marat, et al.
Publicado: (2022)

Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
por: Peters, Anthony E., et al.
Publicado: (2021)

Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines
por: Branca, Luca, et al.
Publicado: (2020)

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Growth differentiation factor‐15, treatment with liraglutide, and clinical outcomes among patients with heart failure
por: Sharma, Abhinav, et al.
Publicado: (2021)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
por: Salah, Husam M., et al.
Publicado: (2021)

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
por: Metra, Marco, et al.
Publicado: (2022)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction
por: Gajewski, Piotr, et al.
Publicado: (2022)

Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1
por: Fudim, Marat, et al.
Publicado: (2023)

Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event
por: Carnicelli, Anthony P., et al.
Publicado: (2021)

Adrenomedullin in heart failure: pathophysiology and therapeutic application
por: Voors, Adriaan A., et al.
Publicado: (2018)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE‐HF extended trial
por: Kleiner Shochat, Michael, et al.
Publicado: (2018)

Synchronized Diaphragmatic Stimulation for Heart Failure With a Reduced Left Ventricular Ejection Fraction Using the VisONE System: A First-in-Patient Study With Extended Population
por: Jorbenadze, Ana, et al.
Publicado: (2022)

Intravenous iron infusion in patients with heart failure: a systematic review and study‐level meta‐analysis
por: Salah, Husam M., et al.
Publicado: (2023)

Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy
por: Nijst, Petra, et al.
Publicado: (2017)

STUDIES IN ULTRAFILTRATION
por: Zinsser, Hans, et al.
Publicado: (1927)

Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial
por: Sharma, Abhinav, et al.
Publicado: (2018)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

INTERVENE‐HF: feasibility study of individualized, risk stratification‐based, medication intervention in patients with heart failure with reduced ejection fraction
por: Zile, Michael R., et al.
Publicado: (2021)

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
por: Lee, Matthew M.Y., et al.
Publicado: (2020)

Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT‐HF risk model
por: DeVore, Adam D., et al.
Publicado: (2021)

Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution
por: Sica, Domenic A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bvl7f98n6q4p3qgk0i4kpl87um